Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans

Marta Bermejo-Jambrina¹, Julia Eder¹, Tanja M Kaptein¹, John L vanHamme², Leanne C Helgers¹, Killian E Vlaming¹, Philip J M Brouwer², Ad C vanNuenen¹, Marcel Spaargaren³, Godelieve J deBree⁴, Bernadien M Nijmeijer¹, Neeltje A Kootstra¹, Marit J vanGils², Rogier W Sanders²,⁵ & Teunis B H Geijtenbeek¹,⁎

Abstract

The current pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and outbreaks of new variants highlight the need for preventive treatments. Here, we identified heparan sulfate proteoglycans as attachment receptors for SARS-CoV-2. Notably, neutralizing antibodies against SARS-CoV-2 isolated from COVID-19 patients interfered with SARS-CoV-2 binding to heparan sulfate proteoglycans, which might be an additional mechanism of antibodies to neutralize infection. SARS-CoV-2 binding to and infection of epithelial cells was blocked by low molecular weight heparins (LMWH). Although dendritic cells (DCs) and mucosal Langerhans cells (LCs) were not infected by SARS-CoV-2, both DC subsets efficiently captured SARS-CoV-2 via heparan sulfate proteoglycans and transmitted the virus to ACE2-positive cells. Notably, human primary nasal cells were infected by SARS-CoV-2, and infection was blocked by pre-treatment with LMWH. These data strongly suggest that heparan sulfate proteoglycans are important attachment receptors facilitating infection and transmission, and support the use of LMWH as prophylaxis against SARS-CoV-2 infection.

Keywords dendritic cells; epithelial cells; Heparan sulfate proteoglycans; low molecular weight heparins; SARS-CoV-2

Subject Category Microbiology, Virology & Host Pathogen Interaction

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019 and can cause coronavirus disease 2019 (COVID-19), an influenza-like disease ranging from mild respiratory symptoms to severe lung injury, multiorgan failure, and death (Yuki et al, 2020; Zhou et al, 2020; Zhu et al, 2020). SARS-CoV-2 spread quickly and has caused a pandemic with a severe impact on global health and world economy (Nicola et al, 2020; World Health Organization, 2020b). SARS-CoV-2 is transmitted predominantly via large droplets expelled from the upper respiratory tract through sneezing and coughing (Ferioli et al, 2020; Harapan et al, 2020) and is subsequently taken up via mucosal surfaces of the nose, mouth, and eyes (Peiris et al, 2003). SARS-CoV-2 infects epithelial cells in the respiratory tract, such as ciliated mucus-secreting bronchial epithelial cells and type 1 pneumocytes in the lung, as well as epithelial cells in the gastrointestinal tract (Hui et al, 2020; Lamers et al, 2020). For more than a year, lockdown strategies and social distancing have been used to mitigate viral spread but due to negative socioeconomic consequences these are not feasible long-term solutions (Brooks et al, 2020; Wright et al, 2020). Currently, several COVID-19 vaccines have been developed and worldwide vaccination programs have been initiated (Mathieu et al, 2021), which aim to curb and stop the pandemic. However, immunocompromised individuals as well as people on immunosuppressive drugs are potentially less protected by vaccinations (preprint: Agha et al, 2021; Boyarsky et al, 2021). Moreover, current vaccine candidates might be less effective against new SARS-CoV-2 variants (Collier et al, 2021; Wang et al, 2021). Thus, there is a need for protective strategies specifically targeting SARS-CoV-2 to prevent further dissemination.
SARS-CoV-2 belongs to the betacoronaviruses, a family that also includes SARS-CoV and MERS-CoV (Letko et al., 2020). The coronavirus Spike (S) protein is a class I fusion protein that mediates virus entry (Bosch et al., 2003; Hulswit et al., 2016). The S protein consists of two subunits: S1 directly engages via its receptor-binding domain (RBD) with host surface receptors (Li et al., 2005; Wang et al., 2013) and S2 mediates fusion between virus and cell membrane (Burkard et al., 2014; Xia et al., 2020).

SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as its main receptor (Hoffmann et al., 2020; Letko et al., 2020). ACE2 is a type I integral membrane protein abundantly expressed on epithelial cells lining the respiratory tract (Hamming et al., 2004) but also the ileum, esophagus, and liver (Zou et al., 2020b) and ACE2 expression dictates SARS-CoV-2 tropism (Lamers et al., 2020). However, it remains unclear whether SARS-CoV-2 requires other receptors for virus entry. Neutralizing monoclonal antibodies against SARS-CoV-2 have been identified that are directed not only at the RBD but also outside the RBD (Brouwer et al., 2020), suggesting that other mechanisms of neutralization or other (co-) receptors might be involved.

Heparan sulfates are expressed by most cells, including epithelial cells, as heparan sulfate proteoglycans and these have been shown to interact with viruses such as HIV-1, HCV, Sindbis virus, and also SARS-CoV (Roderiguez et al., 1995; Byrnes & Griffin, 1998; Jiang et al., 2012; Milewska et al., 2014; Nijmeijer et al., 2020). Recently, it was shown that the S protein of SARS-CoV-2 interacts with heparan sulfates, which might be required for infection (Claussen et al., 2020; Zhang et al., 2020).

Here, we show that heparan sulfate proteoglycans are important for infection of polarized epithelial cells as well as primary nasal cells with SARS-CoV-2. Infection is inhibited by heparin and low molecular weight heparins (LMWH). Mucosal dendritic cell subsets captured SARS-CoV-2 via heparan sulfate proteoglycans. The different DC subsets did not become infected but transmitted SARS-CoV-2 to ACE2-positive cells, which might facilitate virus dissemination. Our findings suggest that heparan sulfate proteoglycans function as attachment receptors for SARS-CoV-2 and LMWH can be used as prophylactics against SARS-CoV-2 or prevent dissemination early after infection.

Results
SARS-CoV-2 pseudovirus binds to heparan sulfates expressed by cells

We incubated Huh7.5 cells that express ACE2 (Fig EV1A) with SARS-CoV-2 pseudovirus, which consists of HIV-1 particles pseudotyped with SARS-CoV-2 S protein (Brouwer et al., 2020). Virus binding was determined by measuring HIV-1 p24 binding by ELISA. SARS-CoV-2 pseudovirus attached to Huh7.5 cells, which was blocked by anti-ACE2 antibodies (anti-ACE2) as well as by neutralizing antibodies from COVID-19 patients (Brouwer et al., 2020) (Fig 1A). Unfractionated (UF) heparin inhibited binding of SARS-CoV-2 pseudovirus to Huh7.5 cells comparable to the neutralizing or anti-ACE2 antibodies (Fig 1A). Enzymatic removal of heparan sulfates on the cell surface by heparinase treatment decreased SARS-CoV-2 virus binding (Figs 1B and EV1B). Exostosin-1 (EXT1) knockdown decreased expression of heparan sulfates on the cell surface (Ren et al., 2018) (Fig 1C). SARS-CoV-2 pseudovirus attached to XG1 cells, which was blocked by UF heparin, whereas knockdown of EXT1 abrogated SARS-CoV-2 pseudovirus binding (Fig 1D). These data suggest that heparan sulfates are important for attachment of SARS-CoV-2 to cells.

Low molecular weight heparins inhibit SARS-CoV-2 infection

To determine the effect of UF heparin on SARS-CoV-2 infection, we infected Huh7.5 cells with SARS-CoV-2 pseudovirus, expressing the luciferase reporter gene, and determined infection by measuring luciferase reporter activity. UF heparin blocked infection in a dose-dependent manner (Fig 2A). Low molecular weight heparin (LMWH) have replaced UF heparin in the clinic as anti-coagulant treatment due to their smaller size and superior pharmacological properties (Kakkar, 2004). LMWH enoxaparin blocked SARS-CoV-2 pseudovirus infection in a dose-dependent manner to similar levels as UF heparin (Fig 2A) without affecting cell viability of Huh7.5 cells (Fig EV1C). Not only enoxaparin but also other clinically approved LMWH blocked binding of SARS-CoV-2 pseudovirus to Huh7.5 cells (Fig 2B). The different LMWH also blocked infection of Huh7.5 cells with SARS-CoV-2 pseudovirus to a similar extent as enoxaparin (Fig 2C).

Next, we investigated whether ACE2 is required for infection in presence of heparan sulfates. Human kidney epithelial 293T cells were not susceptible to SARS-CoV-2 pseudovirus whereas ectopic expression of ACE2 rendered these cells susceptible to SARS-CoV-2 pseudovirus (Figs 2D and EV1D and E). Infection was abrogated by both LMWH enoxaparin and UF heparin to a similar level as antibodies against ACE2 (Fig 2D). The combination of ACE2 antibodies and LMWH enoxaparin or UF heparin blocked infection of 293T-ACE2 cells (Fig 2D). These data suggest that heparan sulfates act as attachment receptors that allow the virus to bind to cells, facilitating infection via ACE2. Next, we investigated whether pre-incubation of SARS-CoV-2 with LMWH prevents ACE2 binding. The primary SARS-CoV-2 isolate (hCoV-19/Italy) interacted with immobilized ACE2 and, notably, pre-treatment of the virus with LMWH did not affect ACE2 binding (Fig EV1F). These data suggest that LMWH prevent virus attachment but do not affect the interaction with ACE2.

Simian Vero E6 cells are highly susceptible to SARS-CoV-2, which causes severe cytopathic effects (CPE) (Zhou et al., 2020), and therefore, we investigated the role of LMWH upon SARS-CoV-2 infection by measuring the cytopathic effects. Infection of VeroE6 with a primary SARS-CoV-2 isolate (hCoV-19/Italy) caused severe CPE as cell viability decreased (Fig 2E), which was counteracted by LMWH enoxaparin in a concentration-dependent manner. These data support an important role for heparan sulfates in ACE2-dependent infection of cells with SARS-CoV-2.

SARS-CoV-2 infection of polarized epithelial cells is blocked by UF heparin and LMWH

The colorectal adenocarcinoma Caco-2 and bronchial adenocarcinoma Calu-3 cells represent models for human intestinal and respiratory epithelial cells, respectively (Artursson et al., 2001; Harcourt et al., 2011). Both cell lines were cultured on microporous filters...
with an air-liquid interface to achieve a polarized monolayer and polarization was monitored by transepithelial electrical resistance (TEER). TEER increased over time to confirm that the cells are polarized after culture of more than 14 days (Fig 3A). Undifferentiated Caco-2 and Calu-3 expressed low levels of ACE2 but polarization of the cells highly increased ACE2 expression (Fig 3B). SARS-CoV-2 pseudovirus bound to both polarized Caco-2 and Calu-3 cells and binding was significantly blocked by LMWH to similar levels as antibodies against ACE2 (Fig 3C and D). The combination of an antibody against ACE2 and LMWH enoxaparin did not further decrease binding. We next infected polarized Calu-3 cells with the primary SARS-CoV-2 isolate for 24 h, washed, and after another 24 h determined productive infection. Infection was determined by measuring SARS-CoV-2 ORF1b transcripts present during infection in cells but also in virus particles. Calu-3-polarized cells were productively infected by the SARS-CoV-2 isolate as shown by the SARS-CoV-2 ORF1b viral transcripts in the cell lysates, and the secretion of SARS-CoV-2 virus particles in the supernatant (Fig 3E and F as well as EV3A and EV3B). Cell viability was not affected by infection as checked by GAPDH expression. Notably, productive infection of Calu-3 cells was inhibited by LMWH to a similar level as ACE2 antibodies (Figs 3E and F as well as EV3A and B). These data suggest that heparan sulfates are required for binding and infection of polarized respiratory epithelial cells with SARS-CoV-2 pseudovirus as well as primary SARS-CoV-2 isolate.

Figure 1. SARS-CoV-2 pseudovirus binds to heparan sulfates.

A Huh7.5 cells were pre-incubated with neutralizing antibody to ACE2 and SARS-CoV-2 pseudovirus was pre-incubated with patient isolated mAb COVA1-18, COVA1-21 and COVA2-15 (10 µg/ml) or UF heparin (250 IU/ml) for 30 min at 37°C. SARS-CoV-2 pseudovirus alone or with blocks was added to the cells for 4 h at 4°C and binding was determined by ELISA.

B Heparan sulfates were removed from Huh7.5 cells by enzymatic treatment with heparinase III for 1 h at 37°C, then washed, and exposed to SARS-CoV-2 pseudovirus for 4 h at 4°C. Treated and untreated cells were subsequently lysed and binding was determined by ELISA.

C Flow cytometry analysis of cell surface expression of heparan sulfates (HS) in control transduced cells or upon CRISPR/Cas9-mediated EXT1 KO (EXT1−/−).

D Control and EXT1−/− XG1 cells were exposed to SARS-CoV-2 pseudovirus or SARS-CoV-2 pseudovirus pre-treated with 250 IU/ml UF heparin for 30 min at 37°C. After incubation for 4 h at 4°C, cells were lysed and binding was measured by ELISA.

Data information: Data show the mean values and error bars are the SEM. Statistical analysis was performed using (A) ordinary one-way ANOVA with Tukey multiple-comparison test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (n = 3), (B) unpaired Student’s t-test with Welch’s correction. *P ≤ 0.05, **P ≤ 0.01 (n = 3), (D) two-way ANOVA with Dunnett’s multiple-comparison test. *P ≤ 0.05, **P ≤ 0.01 (n = 3).
Figure 2. The EMBO Journal | 40: e106765 | 2021

© 2021 The Authors
Heparan sulfate proteoglycans Syndecan 1 and 4 are important for SARS-CoV-2 binding

The heparan sulfate proteoglycan family of Syndecans is particularly important in facilitating cell adhesion of several viruses (Bacsa et al., 2011; Nijmeijer et al., 2020). Therefore, we used the Namalwa B cell line that ectopically expressed Syndecan 1 or Syndecan 4 (Fig EV2A–C) as these Syndecans are expressed by epithelial cells (Hayashida et al., 2006; Teng et al., 2012). Namalwa cells did not express ACE2 (Fig EV1A). Syndecan 1 and Syndecan 4 expressing Namalwa cells bound more efficiently with SARS-CoV-2 pseudovirus than the parental Namalwa cells (Fig 4A). Both UF heparin and LMWH enoxaparin blocked the interaction of Syndecan 1- and 4-expressing cells with SARS-CoV-2 pseudovirus (Fig 4A). Moreover, Syndecan 1-expressing cells did not interact with control pseudovirus lacking the SARS-CoV-2 S protein neither did LMWH enoxaparin affect the interaction (Fig EV2D). Similarly, control pseudovirus did not interact with Huh7.5 cells (Fig EV2D). These data suggest that the interaction of Syndecans with SARS-CoV-2 is specific and depends on the S protein.

Next, we measured binding of primary SARS-CoV-2 to Syndecan expressing cells. The primary SARS-CoV-2 isolate attached to both Syndecan 1 and Syndecan 4 expressing cells and LMWH enoxaparin blocked binding to background levels similar to those observed for the parental control cells (Figs 4B and EV3B). Cell viability was unaffected as determined by GAPDH expression. These data indicate that Syndecan 1 and 4 are important heparan sulfate proteoglycans involved in SARS-CoV-2 binding and infection.

Neutralizing antibodies against SARS-CoV-2 interfere with SARS-CoV-2 binding to Syndecan 1

Several antibodies against SARS-CoV-2 were isolated from COVID-19 patients, and some of these were potent neutralizing antibodies against SARS-CoV-2 that target the RBD (COVA1-15, COVA1-18) as well as the non-RBD (COVA1-21) of the S protein (Brouwer et al., 2020). Therefore, we investigated whether antibodies against SARS-CoV-2 interfere with the interaction of heparan sulfates with SARS-CoV-2. We treated SARS-CoV-2 pseudovirus with different S protein targeting antibodies and measured virus binding to ACE2-negative Syndecan 1-expressing Namalwa cells. Notably, only the three neutralizing antibodies against SARS-CoV-2, COVA-1-15, 1-18, and 1-21 blocked the interaction of SARS-CoV-2 pseudovirus with Syndecan 1 in a concentration-dependent manner and to similar levels as observed for LMWH (Fig 5A). In contrast, non-neutralizing antibodies did not inhibit virus binding (Fig 5A).
Next, we determined the ability of the S protein antibodies to block binding of the primary SARS-CoV-2 isolate to ACE2-negative Syndecan 1-expressing Namalwa cells. Similar as observed for SARS-CoV-2 pseudovirus, the three neutralizing COVA antibodies blocked the interaction of the SARS-CoV-2 isolate with Syndecan 1, whereas non-neutralizing antibody COVA-1-27 did not block...
neutralizing RBD and non-RBD antibodies against SARS-CoV-2 interfere with SARS-CoV-2 binding to heparan sulfate proteoglycans and that this binding is facilitated by the SARS-CoV-2 S protein.

SARS-CoV-2 targets dendritic cells for dissemination

SARS-CoV-2 infects cells in nasal mucosa, lung, and the intestinal tract but mechanisms for dissemination of the virus from the respiratory to the intestinal tract remain unclear. Mucosal DC subsets might be involved in promoting local infection of epithelial cells in these tissues through capture as well as virus dissemination as these antigen-presenting cells after activation migrate to the lymphoid tissues to present antigens to T cells. We therefore investigated whether SARS-CoV-2 infects different mucosal DC subsets and whether DCs can transmit the virus to other cells. We differentiated monocytes to DCs, which is a model for submucosal DC, and also isolated primary human Langerhans cells (LCs) as this DC subset resides in squamous mucosa of different tissues including nasal and intestinal mucosa (Merad et al., 2008; Nijmeijer et al., 2019). Both monocyte-derived DCs and primary LCs efficiently bound SARS-CoV-2 pseudovirus and binding was inhibited by UF heparin as well as LMWH enoxaparin (Fig 6A and B). Notably, neither DCs nor LCs were infected by SARS-CoV-2 pseudovirus (Fig 6C), which is due to the absence of ACE2 expression on both subsets (Fig 6D). These data suggest that primary DC subsets capture SARS-CoV-2 via heparan sulfate proteoglycans but this does not lead to infection.

Different DC subsets transmit HIV-1 to target cells independent of productive infection (Geijtenbeek et al., 2000; Gurney et al., 2001; and Fig 6B).
We therefore incubated both DCs and LCs with SARS-CoV-2 pseudovirus and after washing away unbound virus, co-cultured the DC subsets with susceptible ACE2 expressing Huh7.5 cells (Fig 6E). Notably, co-culture of both virus-exposed DC subsets with Huh7.5 cells led to infection of the latter, as determined by luciferase reporter activity and infection was blocked by pre-treatment of pseudovirus with UF heparin and LMWH enoxaparin (Fig 6F and G). Next, DCs and LCs were incubated with the primary SARS-CoV-2 isolate and after extensive washing added to ACE2-positive Huh7.5 cells. Infection of Huh7.5 cells was determined by quantitative PCR after removing leftover DCs or LCs. Notably, both SARS-CoV-2-exposed DCs and LCs transmitted the virus to Huh7.5 cells as shown by infection of Huh7.5 cells, and transmission was inhibited by LMWH enoxaparin (Figs 6H and I as well as EV4A and B). These data suggest that both DCs and LCs efficiently capture SARS-CoV-2 via heparan sulfate proteoglycans and transmit the virus to ACE2 expressing target cells, which could be involved in virus dissemination from mucosal sites to lymphoid tissues.

Figure 5. Neutralizing antibodies against SARS-CoV-2 interfere with SARS-CoV-2 binding to Syndecan 1.

A SARS-CoV-2 pseudovirus was pre-treated with LMWH enoxaparin (250 IU/ml), or different neutralizing antibodies against SARS-CoV-2 (COVA1-18, COVA1-21 and COVA2-15) and a human IgG1 isotype control at concentrations of 100 pg/ml, 500 pg/ml, 1 ng/ml, 5 ng/ml, 10 ng/ml, and 50 ng/ml for 30 min at 37°C. Binding of pseudovirus to Syndecan 1-expressing Namalwa cells in absence or presence of LMWH enoxaparin or antibodies was determined by ELISA.

B SARS-CoV-2 isolate (hCoV-19/Italy) was pre-treated for 30 min at 37°C with either LMWH enoxaparin (250 IU/ml) or one of the following neutralizing antibodies (COVA1-18, 1-21, and 2-15), a non-neutralizing antibody (COVA2-27), or a human IgG1 isotype control, all at the concentration of 1 pg/ml. SARS-CoV-2 isolate alone or with blocks was added at a concentration of 100 TICD/ml. Detection of virus binding to Syndecan 1-expressing Namalwa cells was measured by quantitative real-time PCR.

Data information: Data show the mean values and error bars are the SEM. Statistical analysis was performed using (A) ordinary one-way with Dunnett’s multiple-comparison test. *P ≤ 0.05, **P ≤ 0.01 (n = 3), (B) ordinary one-way with Tukey’s multiple-comparison test. *P ≤ 0.05, **P ≤ 0.01 (n = 2 measured in duplicate).

Source data are available online for this figure.
Figure 6.
SARS-CoV-2 attaches to and infects primary nasal cells via heparan sulfate proteoglycans

Nasal epithelium is an important target for SARS-CoV-2 infection. Higher viral loads are detected in nasal and nasopharyngeal swabs compared with throat swabs (Wang et al., 2020; Tsang et al., 2021). Here, we isolated nasal cells from healthy volunteers by brushing the inside of the nasal cavity. Epithelial cells are a major component of the isolated cells as shown by high percentage of cells positive for the epithelial cell marker EpCAM (Fig 7A). Also, hematopoietic cells were present in the nasal cell fraction as shown by the expression of the hematopoietic cell marker CD45 (Fig 7A). Next, we analyzed Syndecan 1 and 4 transcripts in the nasal fraction as well as expression of ACE2. Especially high levels of Syndecan 1 transcripts were determined in the nasal fraction compared with those observed for polarized Calu-3 cells (Figs 7B and EV5A). ACE2 transcript were also detected, suggesting that SARS-CoV-2 could directly infect nasal cells (Figs 7B and EV5A) (Sunghan et al., 2020). We first investigated binding of primary SARS-CoV-2 isolate to the nasal cells. SARS-CoV-2 attached to the nasal cells from different donors and binding was blocked by LMWH enoxaparin (Figs 7C and EV5B). Primary nasal cells were exposed to SARS-CoV-2 and cultured for 24 h. Viability was not affected as measured by GAPDH expression. Notably, we observed high levels of SARS-CoV-2 ORF1b in cell lysates (Figs 7D and EV5C). Infection was inhibited by ACE2 block and, importantly, LMWH treatment blocked infection of SARS-CoV-2 as shown by decreased ORF1b in cell-lysate (Figs 7D and EV5C). These data suggest that heparan sulfate proteoglycans expressed by the nasal epithelium are involved in SARS-CoV-2 binding and infection.

Discussion

SARS-CoV-2 interacts with ACE2 to infect cells. Recent studies suggest that heparan sulfates might interact with S protein to enhance viral attachment (Clausen et al., 2020; Zhang et al., 2020). Moreover, Clausen et al. (2020) show that heparan sulfate binding to SARS-CoV-2 facilitates ACE2 interactions. Here, we show that heparan sulfate proteoglycans on primary epithelial cells and primary dendritic cell subsets interact with both pseudotyped and primary SARS-CoV-2. We have identified Syndecan 1 and 4 as important attachment receptors for SARS-CoV-2. Interestingly, neutralizing antibodies against SARS-CoV-2 prevented the interaction of SARS-CoV-2 with Syndecan 1, suggesting that antibodies targeting the interaction of SARS-CoV-2 with heparan sulfates might also neutralize infection similarly to what was shown for antibodies against ACE2. Moreover, we identified a role for heparan sulfate proteoglycans during transmission by primary mucosal DC subsets, which is independent of infection. Both UF heparin and LWMH efficiently reduced infection and transmission of SARS-CoV-2. Moreover, we show that LMWH efficiently decrease infection of primary nasal epithelial cells. Thus, heparan sulfate proteoglycans function as attachment receptors for SARS-CoV-2 on primary epithelial and dendritic cells, and targeting these receptors might prevent infection.

Our data indicate that SARS-CoV-2 binding to polarized colorectal and respiratory epithelial cells is facilitated by heparan sulfates, supporting a role for heparan sulfate proteoglycans as attachment receptors. Moreover, infection of polarized respiratory epithelial cells by SARS-CoV-2 hCoV-19/Italy strain as well as pseudovirus was inhibited by LMWH to a similar level as anti-ACE2 antibodies. Combinations of LMWH with antibodies did not further decrease infection. These data suggest that SARS-CoV-2 attaches to cells via heparan sulfate proteoglycan, which facilitates interaction with ACE2 and subsequent infection. Indeed, treatment of SARS-CoV-2 with LMWH blocked heparan sulfate binding sites of the virus while it did not affect viral binding capacity to ACE2, suggesting that attachment of SARS-CoV-2 to heparan sulfate proteoglycans can facilitate ACE2 interaction.

Neutralizing antibodies against SARS-CoV-2 are a potential therapy for COVID-19 patients and most potent monoclonal neutralizing antibodies target the RBD site of the S protein thereby preventing interaction of S protein with ACE2 (Brouwer et al., 2020). However, neutralization antibodies have also been isolated that target non-RBD sites of the S protein. Indeed, COVA1-21 targets a non-RBD site for SARS-CoV-2 on primary epithelial and dendritic cells, and targeting these receptors might prevent infection.
another mechanism. We screened different antibodies isolated from COVID-19 patients (Brouwer et al., 2020) for blocking SARS-CoV-2 binding to Syndecan 1. Two RBD antibodies COVA1-18 and COVA2-15 and one non-RBD antibody COVA1-21 were identified that blocked interaction of Syndecan 1 with SARS-CoV-2 pseudovirus as well as the SARS-CoV-2 hCoV-19/Italy strain. Notably, these three antibodies are potent neutralizing antibodies against SARS-CoV-2 (Brouwer et al., 2020). Most non-neutralizing antibodies did not interfere with SARS-CoV-2 binding to Syndecan 1. These data suggest that blocking the interaction of SARS-CoV-2 with heparan sulfate proteoglycans might be a new mechanism of neutralization.

Our data strongly suggest that the S protein from SARS-CoV-2 is crucial to the interaction with heparan sulfate proteoglycans and Syndecan 1, as antibodies against the S protein blocked binding of both SARS-CoV-2 pseudovirus and a SARS-CoV-2 isolate to Syndecan 1-expressing Namalwa cells. Moreover, control pseudoviruses lacking the S protein did neither interact with Huh7.5 cells nor Syndecan 1-expressing cells, further supporting the specificity of the interaction between S protein from SARS-CoV-2 and heparan sulfate proteoglycans.

Different DC subsets are present in mucosal tissues to capture pathogens for antigen presentation. After pathogen interactions, DCs migrate into lymphoid tissues (Randolph et al., 2005). Several viruses, such as HIV-1 and Dengue virus, hijack DC functions for dissemination (Geijtenbeek et al., 2000; Pham et al., 2012). Primary LCs and DCs efficiently captured SARS-CoV-2 via heparan sulfate proteoglycans. Previously we have shown that LCs express Syndecan 4 (Nijmeijer et al., 2020) and DCs express Syndecan 3 and Syndecan 4 (de Witte et al., 2007a). Thus, our data suggest that both Syndecan 3 and 4 might be involved in SARS-CoV-2 capture. Both LCs and DCs did not express ACE2 and were not infected by SARS-CoV-2 pseudovirus. However, co-culture of SARS-CoV-2-exposed LCs and DCs with ACE2 cell surface receptors (1 h at 37°C) or after pre-treatment with antibodies against ACE2 cell surface receptors (1 h at 37°C) or after pre-treatment with LMWH enoxaparin (250 IU/ml) for 30 min at 37°C. Detection of viral binding after 4 h at 4°C (C) and persistently infected cells lysed after 24 h at 37°C (D) was determined by quantitative real-time PCR.

Data information: Data show the mean values and error bars are the SEM. Statistical analysis was performed using (C, D) ordinary one-way ANOVA with Tukey’s multiple-comparison test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 (C) (n = 3), (D) (n = 3 in duplicate).
The upper airways and nasal epithelium might be the primary route of infection as higher viral load have been found in nasal swabs when compared to throat swabs (Zou et al., 2020a). Moreover, nasal epithelial cells express ACE2 and the cellular serine protease TMPRSS2 (Sungnak et al., 2020). We have isolated nasal cells from healthy volunteers using a nasal brush and the majority of cells were EpCAM-positive epithelial cells and some hematopoietic cells, most likely lymphocytes and myeloid cells. Syndecan 1 and 4 transcripts were detected at high levels in nasal cell fraction, suggesting that Syndecans might be involved in virus interactions. Our data support an important role for nasal cells as the first target for SARS-CoV-2 as nasal cells efficiently captured primary SARS-CoV-2 and were also infected by SARS-CoV-2. LMWH blocked capture and infection of the nasal cells. Interestingly, the nasal cells were not cultured as done in previous studies (Müller et al., 2013; Vanders et al., 2019) suggesting that the nasal epithelial cells are a direct target for SARS-CoV-2 and that heparan sulfate proteoglycans are involved in the infection.

LMWH are already used as subcutaneous treatment of COVID-19 patients to prevent systemic clotting (World Health Organization, 2020a; Zhai et al., 2020). Interestingly, here we have identified an important ability of LMWH to directly block SARS-CoV-2 binding and infection of epithelial cells as well as preventing virus transmission. Our data support the use of LMWH as prophylactic treatment for SARS-CoV-2 as well as a treatment option early in infection to block further infection and dissemination. Vaccination programs are currently running worldwide but it remains unclear whether this is sufficient for specific patients who are immunocompromised or suffer from other diseases that prevent an efficient immune response upon vaccination. LMWH prophylaxis might also be used when new SARS-CoV-2 variants arise that are not efficiently counteracted by the current vaccines.

Materials and Methods

Reagents and antibodies

The following antibodies were used (all anti-human): ACE2 (R&D), (Heparan Sulfate (clone F58-10E4) (Ambsbio), digested Heparan (clone F69-3G10) (Ambsbio), CD1a-APC mouse IgG1 (BD Biosciences, San Jose, CA, USA), CD207-PE (langerin) mouse IgG1 (#IM3577), PerCP-Cy5.5-conjugated mouse IgG1 EPCAM 347199) (BD Bioscience), PE-conjugated mouse IgG1 E-Cadherin (FAB1881P) (R&D Systems), APCcy-conjugated mouse IgG1 CD45 (557833) (BD Bioscience), APC-conjugated CD14 (21620146sp) (ImmunoTools), PE-conjugated mouse IgG1 CD11b (101208) (Biologend). FITC-conjugated goat-anti-mouse IgM (#31992) (Invitrogen), AF488-conjugated donkey-anti-mouse IgG2b (Invitrogen). Flow cytometric analyses were performed on a BD FACS Canto II (BD Biosciences). Data were analyzed using FlowJo vX.0.7 software (TreeStar).

The following reagents were used: unfractionated (UF) heparin, 5,000 IE/ml (LEO), low molecular weight heparins (LMWH): dalteparin, 10,000 IE anti-Xa/ml (Pfizer), tinzaparin, 10,000 IE anti-Xa/0.5 ml (LEO), enoxaparin, 6000 IE (60 mg)/0.6 ml (Sanofi), nadroparin, 9,500 IE anti-Xa/ml (Aspen). Heparinase III from Flavobacterium heparium, EC 4.2.2.8, Batch 010, (Ambsbio). Biotinylated SARS-CoV-2 S protein as well as neutralizing and non-neutralizing COVA antibodies was generated as described previously (Brouwer et al., 2020).

Cell lines

The Simian kidney cell line VeroE6 (ATCC® CRL-1586™) was maintained in CO2 independent medium (Gibco Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). Culture was maintained at 37°C without CO2. Huh7.5 (human hepatocellular carcinoma) cells received from Dr. Charles M. Rice (Lindenbach et al., 2005) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). Medium was supplemented with 1mM Hepes buffer (Gibco Life Technologies). The human B cell line Namalwa (ATCC, CRL-1432) and Namalwa cells stably expressing human Syndecan 1, Syndecan 2, Syndecan 3 and Syndecan 4 (Zhang et al., 2001) were a gift from Dr. Guido David and Dr. Philippe A Gallay. The cells were maintained in RPMI 1640 medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), penicillin/streptomycin (10 µg/ml), and 1 mM sodium pyruvate (Thermo Fisher). The expression of the different Syndecans was validated by PCR analysis using specific primers aimed against Syndecans. The human multiple myeloma cell line XG-1 was cultured in Iscove’s modified Dulbecco’s medium (Invitrogen Life Technologies) containing 10% fetal bovine serum, 100 U/ml of penicillin, and 100 µg/ml of streptomycin. The medium was further supplemented with 500 µg/ml of interleukin 6 (Prospec). The CRISPR-Cas9 knockout for Ext1 has been described previously (Ren et al., 2018). The human embryonic kidney 293T/17 cells (ATCC, CRL-11268) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). The human epithelial Caco-2 cells (ATCC, HTB-37™) as well as the human lung epithelial Calu-3 cells (ATCC® HTB-55™) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). The human epithelial Caco-2 cells (ATCC, HTB-37™) as well as the human lung epithelial Calu-3 cells (ATCC® HTB-55™) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). The human epithelial Caco-2 cells (ATCC, HTB-37™) as well as the human lung epithelial Calu-3 cells (ATCC® HTB-55™) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). The human epithelial Caco-2 cells (ATCC, HTB-37™) as well as the human lung epithelial Calu-3 cells (ATCC® HTB-55™) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). The human epithelial Caco-2 cells (ATCC, HTB-37™) as well as the human lung epithelial Calu-3 cells (ATCC® HTB-55™) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). The human epithelial Caco-2 cells (ATCC, HTB-37™) as well as the human lung epithelial Calu-3 cells (ATCC® HTB-55™) were maintained in Dulbecco’s modified Eagle’s medium (Gibco Life Technologies) containing 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml).
were prepared as described previously (de Witte et al., 2007b; Sarrami-Forooshani et al., 2014). Briefly, skin grafts were obtained using a dermatome (Zimmer Biomet, Indiana USA). After incubation with Dispase II (1 U/ml, Roche Diagnostics), epidermal sheets were separated from dermis, washed, and cultured in IMDM (Thermo Fischer Scientific, USA) supplemented with 10% FCS, gentamicin (20 µg/ml, Centrafarm, Netherlands), penicillin/streptomycin (10 µU/ml and 10 µg/ml, respectively; Invitrogen) for 3 days after which LCs were harvested. Purity of LCs was routinely verified by flow cytometry using antibodies directed against CD207 (langerin) and CD1a (Fig EV2F).

Primary nasal epithelial cells were obtained from healthy volunteers. Cells were isolated from the lower nasal cavity with a brush after which they were transferred into CO2 independent medium ( Gibco Life Technologies) supplemented with 10% fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 µg/ml). Cell surface receptor expression was determined by flow cytometry.

SARS-CoV-2 pseudovirus production

For production of single-round infection viruses, human embryonic kidney 293T/17 cells (ATCC, CRL-11268) were co-transfected with an adjusted HIV-1 backbone plasmid (pNL4-3.Luc.R-S-) containing previously described stabilizing mutations in the capsid protein (PMID: 12547912) and a firefly luciferase gene in the nef open reading frame (1.35 µg) and psARS-CoV-2 expressing SARS-CoV-2 S protein (0.6 µg) (GenBank; MN908947.3) (Brouwer et al., 2020). For single-round infection viruses lacking S protein, an empty vector (pcDNA3.1(+), Thermo Fisher Scientific, #V79020.) was added instead. Transfection was performed in 293T/17 cells using GeneJuice (Novagen, USA) transfection kit according to the manufacturer’s protocol. At day 3 or day 4, pseudotyped SARS-CoV-2 virus particles were harvested and filtered over a 0.2-µm nitrocellulose membrane (Sartorius Stedim, Göttingen, Germany). SARS-CoV-2 pseudovirus productions were quantified by p24 ELISA (Perkin Elmer Life Sciences).

SARS-CoV-2 production

All experiments with SARS-CoV-2 isolates were performed in a BSL-3 laboratory, following all appropriate safety and security protocols approved by the Amsterdam UMC BioSafetyGroep and performed under the environmental license obtained from the municipality Amsterdam. The following reagent was obtained from Dr. Maria R. Capobianchi through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate Italy-INMI1, NR-52284, originally isolated January 2020 in Rome, Italy. VeroE6 cells (ATCC® CCL-132) were inoculated with the SARS-CoV-2 isolate and used for reproduction of virus stocks. Cytopathic effect (CPE) formation was closely monitored by tissue culture infectious dose (TCID50) on VeroE6 cells. In brief, VeroE6 cells were seeded in a 96-well plate at a cell density of 8,000 cells in 100 µl. After 24 h, cells were inoculated with a fivefold serial dilution of SARS-CoV-2 isolate in quadruplicate. Cell cytocitotoxicity was measured using the MTT assay 48 h after infection. Loss of MTT staining as determined by spectrometry (OD 580 nm) is indicative of the (CPE) of SARS-CoV-2. The virus titer was determined as TCID50/ml and calculated based on the Reed Muench method (Reed & Muench, 1938).

Pseudovirus infection assays

HuH7.5 and 293T cells were exposed to 95 ng of single-round SARS-CoV-2 pseudovirus. Primary dendritic cell subsets were exposed to 190 ng and polarized Caco2 and Calu3 cells to 477.62 ng of single-round SARS-CoV-2 pseudovirus. Virus was pre-incubated with 250 IU/ml LMWH or UF heparin to addition to the cells. Viral protein production was quantified after 5 days at 37°C by measuring luciferase reporter activity. Luciferase activity (relative light units (R.L.U.)) was measured using the Luciferase assay system (Promega, USA) according to the manufacturer’s instructions.

Virus binding

In order to determine SARS-CoV-2 binding, target cells were seeded in a 96-well plate at a density of either 10,000 cells in 10 µl for adherent cells the day before or 100,000 cells in 10 µl for suspension cells the same day. All cells were exposed to either 95 ng/ml of SARS-CoV-2 pseudovirus or SARS-CoV-2 isolate (hCoV-19/Italy, 100 TCID/ml) for 4 h at 4°C. After 4 h, cells were washed extensively to remove unbound virus. Cells incubated with SARS-CoV-2 pseudovirus were lysed and binding and internalization were quantified by RETRO-TEK HIV-1 p24 ELISA according to manufacturer instructions (ZeptoMetrix Corporation). Cells incubated with SARS-CoV-2 isolate (hCoV-19/Italy) were lysed with AVL buffer and RNA was isolated with the QIAamp Viral RNA Mini Kit (Qiagen) according to the manufacturer’s protocol.

SARS-CoV-2 WT infection

VeroE6 cells were seeded at a density of 10,000 cells in 100 µl in a 96-well plate. After 24 h, the cells were exposed to the SARS-CoV-2 isolate (hCoV-19/Italy, 100 TCID/ml) for 48 h. Additionally, SARS-CoV-2 isolate was pre-incubated with 250 IU/ml of LMWH exonaparin prior to cell inoculation. Infection was measured after 48 h at 37°C by MTT and determined by cell viability. Polarized Calu-3 cells that had initially been seeded with 250,000 cells/transwell (6.5 mm filter insert) prior to infection were incubated with SARS-CoV-2 isolate (hCoV-19/Italy, 0.5 TCID/ml) for 24 h, after which cells were washed thoroughly and new medium was added. Viral infection and secretion were determined by RT-PCR measurement of ORF-1b transcript. Primary nasal epithelial cells seeded at a density of 50,000–100,000 cells in 100 µl were incubated with SARS-CoV-2 isolate (hCoV-19/Italy, 100 TCID/ml) for 24 h after which ORF-1b transcript was determined by RT-PCR.

Tetrazolium dye colorimetric cell viability (MTT) assay

MTT solution was added to VeroE6 cells and incubated for 2 h at 37°C. After removing the MTT solution, MTT solvent containing 4 mM HCl and 1% Nonidet P-40 (NP40) in isopropanol was added to the cells. Homogenous solution was measured at optical density between 580 and 655 nm.

293T Transfection with ACE2

To generate cells expressing human ACE2, human embryonic kidney 293T/17 cells were transfected with pcDNA3.1(−)hACE2
(Addgene plasmid #1786). Transfection was performed in 293T/17 cells using the GeneJuice (Novagen, USA) transfection kit according to the manufacturer’s protocol. At 24 h post-transfection, cells were washed with phosphate-buffered saline (PBS) and cultured for recovering at 37°C for 24 h in Dulbecco’s MEM supplemented with 10% heat-inactivated fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 U/ml). After 24 h of recovery, cells were cultured in media supplemented with G418 (5 mg/ml) (Thermo Fisher) and passage for 3 weeks at 37°C. Surviving clones were analyzed for ACE2 expression via flow cytometry and quantitative real-time PCR.

**Transmission assays and co-culture**

Per condition, 100,000 DCs or LCs/100 µl were exposed to 191.05 ng of pseudotyped SARS-CoV-2 or pseudotyped SARS-CoV-2 pre-incubated with 250 IU/ml UF heparin or LMWH enoxaparin for 30 min at 37°C. After 4 h at 37°C, cells were harvested, extensively washed to remove unbound virus, and co-cultured with HuH7.5 for 5 days at 37°C. After 5 days, DCs or LCs were washed away and HuH7.5 cells were analyzed with the Luciferase assay system (Promega, USA) according to the manufacturer’s instructions to determine infection based on luciferase reporter activity. Similarly, DCs or LCs were also exposed to either SARS-CoV-2 isolate (hCoV-19/Italy, 100 TCID/ml) or SARS-CoV-2 isolate pre-incubated with 250 IU/ml LMWH enoxaparin (30 min at 37°C). After 24 h at 37°C, cells were extensively washed to remove unbound virus and co-cultured with HuH7.5 for 24 h at 37°C. Subsequently, HuH7.5 cells were again washed extensively to remove DCs or LCs and HuH7.5 cells were lysed for isolation of viral RNA.

**RNA isolation and quantitative real-time PCR**

Viral RNA in cells and supernatant was isolated with the QIAamp Viral RNA Mini Kit (Qiagen) according to the manufacturer’s protocol. cDNA was synthesized with the M-MLV reverse transcriptase kit (Promega) and diluted 1 in 5 before further application. Cellular mRNA of cells not exposed to virus was isolated with an mRNA Capture kit (Roche) and cDNA was synthesized with a reverse transcriptase kit (Promega). PCR amplification was performed in the presence of SYBR green in a 7500 Fast Realtime PCR System (ABI). Specific primers were designed with Primer Express 2.0 (Applied Biosystems). Primer sequences used for mRNA expression were obtained from GeneLnc (Novagen, USA) transfection kit according to the manufacturer’s protocol. At 24 h post-transfection, cells were washed with phosphate-buffered saline (PBS) and cultured for recovering at 37°C for 24 h in Dulbecco’s MEM supplemented with 10% heat-inactivated fetal calf serum (FCS), L-glutamine, and penicillin/streptomycin (10 U/ml). After 24 h of recovery, cells were cultured in media supplemented with G418 (5 mg/ml) (Thermo Fisher) and passage for 3 weeks at 37°C. Surviving clones were analyzed for ACE2 expression via flow cytometry and quantitative real-time PCR.

**Biosynthesis inhibition and enzymatic treatment**

HuH7.5 cells were treated in D-PBS/0.25% BSA with 46 milliunits heparinase III (Amsbio) for 1 h at 37°C, washed, and used in subsequent experiments. Enzymatic digestion was verified by flow cytometry using antibodies directed against heparan sulfates and digested heparan sulfates.

**Human ACE2 protein binding**

Recombinant human ACE2 protein, kindly provided by the laboratory of Dr. Rogier Sanders, was coated at a concentration of 2 µg/ml on a high binding plate (Nunc MaxiSorpTM flat-bottom, Thermo Fisher) at 4°C. After overnight incubation, wells were blocked with 2% BSA for 30 min at 37°C before being washed extensively. SARS-CoV-2 isolate (hCoV-19/Italy, 20,000 TCID/ml) was added for 4 h at 4°C at a total of 50 µl. After 4 h, wells were lysed and SARS-CoV-2 ORF-1b transcript was determined by quantitative real-time PCR.

**Statistics**

All results are presented as mean ± SEM and were analyzed by GraphPad Prism 8 software (GraphPad Software Inc.). A two-tailed, parametric Student’s t-test for paired observations (differences within the same donor) or unpaired observation, Mann–Whitney tests (differences between different donors that were not normally distributed) was performed. For unpaired, non-parametric observations, a one-way ANOVA or two-way ANOVA test with post hoc analysis (Tukey’s or Dunnet’s) was performed. Statistical significance was set at *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

**Data availability**

This study includes no data deposited in external repositories.

**Expanded View for this article is available online.**

**Acknowledgements**

We thank Jonne Snitselaar and Yoann Aldon for help with production of antibodies and Hildo Lantermans for help with the KG1FXT1 KO cell lines. This research was funded by the Netherlands Organisation for Health Research and Development (ZonMw) together with the Stichting Proefdierverrij (ZonMw MKMD COVID-19 grant nr. 114025008 to TBHG), ZonMw (446002508 to GJB) and European Research Council (Advanced grant nr. 700424 to TBHG), Amsterdam UMC PhD grant and two COVID-19 grants from the Amsterdam institute for Infection & Immunity (to TBHG, RWS, and MJG). This study was also supported by the Netherlands Organization for Scientific Research (NWO) through a Vici grant (to RWS), and by the Bill & Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (CAVD), grant INV-002022 (to RWS).

**Author contributions**

MB-J and JE conceived and designed experiments. MB-J, JE, TMK, LCH, JLH performed the experiments and contributed to scientific discussion. PJMB, KEV, MS, GJB, BMN, NAK, MJG, and RWS contributed essential research materials and scientific input. MB-J, JE, TMK, and TBHG analyzed and interpreted data.
JE, MB-J, and TBHG wrote the manuscript with input from all listed authors. TBHG was involved in all aspects of the study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

Agha M, Blake M, Chilleo C, Wells A, Haidar G (2021) Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv https://doi.org/10.1101/2021.04.06.21254949 [PREPRINT]

Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. *Adru Drug Deliv Rev* 46: 27–43

Bacsia S, Karasneh G, Dosa S, Liu J, Valyi-Nagy T, Shukla D (2011) Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection. *J Gen Virol* 92: 733–743

Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. *J Virol* 77: 8801–8811

Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garaoniak-Wang JM, Segev DL, Paik J (2021) Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. *Ann Rheum Dis* 80: 1098–1099

Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ (2020) The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet* 395: 912–920

Brouwer PJM, Caneles TG, van der Straaten K, Snitselaar JL, Aldon Y, Baranger S, Torres JL, Okba NMA, Claireaux M, Kerster G et al (2020) Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science* 369: 643–650

Burkard C, Verheije MH, Wicht O, van Kasteren SI, van Kuppeveld FJ, Merad M, Ginhoux F, Collin M, Harcourt JL, Caidi H, Anderson LJ, Haynes LM (2011) Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection. *J Virol Methods* 174: 144–149

Hayashida K, Johnson DR, Goldberger O, Park PW (2006) Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. *J Biol Chem* 281: 24365–24374

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 181: 271–280

Hui KPY, Cheung M-C, Perera RAPM, Ng K-C, Bui CHT, Ho JCW, Ng MM, Kuok DIT, Shih KC, Tsao S-W et al (2020) Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med* 8: 687–695

Hulsut RJ, de Haan CA, Bosch BJ (2016) Coronavirus spike protein and tropism changes. *Adru Vius Res* 96: 29–57

Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo C (2012) Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. *J Virol* 86: 7256–7267

Kakkar AK (2004) Low- and ultra-low-molecular-weight heparins. *Best Pract Res Clin Haematol* 17: 77–87

Lamers MM, Beumer J, van der Vaart J, Knoop S, Puschhof J, Breugem T, Ravelli RBC, Paul van Schayck J, Myktyzen AZ, Duimel HQ et al (2020) SARS-CoV-2 productively infects human gut enterocytes. *Science* 369: 50–54

Letko M, Marzi A, Munster V (2020) Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* 5: 562–569

Li F, Li W, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science* 309: 1864–1868

Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA et al (2005) Complete replication of hepatitis C virus in cell culture. *Science* 309: 623–626

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasel J, Appel C, Giacinto G, Rodés-Cabau J (2021) A global database of COVID-19 vaccinations. *Nat Hum Behav* 5: 947–953

Merad M, Ghinhoux F, Collin M (2008) Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. *Nat Rev Immunol* 8: 935–947

Mesman AW, Zijlstra-Willems EM, Kapteyn TM, de Swart RL, Davis ME, Ludlow M, Duprex WP, Gack MU, Gringhuis SJ, Geijtenbeek TB (2014) Measles virus suppresses RIG-I-like receptor activation in dendritic cells via DC-SIGN-mediated inhibition of P1P phosphatases. *Cell HostMicrobe* 16: 31–42

Milewski A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K (2014) Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. *J Virol* 88: 13221–13230

Müller L, Brighton LE, Carson JL, Fischer 2nd WA, Jaspers I (2013) Culturing of human nasal epithelial cells at the air liquid interface. *J Virol* e05846
de Witte L, Bobardt M, Chatterji U, Deggeest G, David G, Geijtenbeek TB, Gallay P (2007a) Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci USA 104: 19464–19469

de Witte L, Nabi妥ov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, Piguet V, van Kooyk Y, Geijtenbeek TB (2007b) Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 13: 367–371

World Health Organization (2020a) Clinical management of COVID-19. Interim guidance 27 May 2020, p. 62. Geneva: WHO Press – World Health Organization

World Health Organization (2020b) Timeline of WHO’s response to COVID-19. Wright L, Steptoe A, Fancourt D (2020) Are we all in this together?

Longitudinal assessment of cumulative adversities by socioeconomic position in the first 3 weeks of lockdown in the UK. J Epidemiol Community Health 74: 683–688

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S et al (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harvests a high capacity to mediate membrane fusion. Cell Res 30: 343–355

Yuki K, Fujogi M, Koutsogiannaki S (2020) COVID-19 pathophysiology: a review. Clin Immunol 215: 108427

Zhao Z, Li C, Chen Y, Gerotziakas G, Zhang Z, Wan J, Liu P, Elalamy I, Wang C (2020) Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost 120: 937–948

Zhang Q, Chen ZZ, Swaroop M, Xu M, Wang L, Jee L, Wang AQ, Pradhan M, Hagen N, Chen L et al (2020) Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov 6: 80

Zhang Z, Coomans C, David G (2001) Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling: evidence in support of the "cooperative end structures" model. J Biol Chem 276: 41921–41929

Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270–273

Zhu NA, Zhang D, Wang W, Li X, Yang BO, Song J, Xiao H, Huang B, Shi W, Lu R et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727–733

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J et al (2020a) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382: 1177–1179

Zou X, Chen K, Zou J, Han P, Hao J, Han Z (2020b) Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 14: 185–192

License: This is an open access article under the terms of the Creative Commons Attribution-NoCom mercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.